Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Postoperative Analgesia After Laparoscopic Living Donor Nephrectomy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Marianne Myhre, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT01059331
First received: January 28, 2010
Last updated: March 20, 2014
Last verified: March 2014
  Purpose

The aim of the study is to investigate if perioperative administration of pregabalin vil reduce postoperative pain and the postoperative need for intravenous opioids compared with todays standard treatment which consist of paracetamol, corticoids and ketobemidone.

In addition potential sideeffects as sedation and effect on cognitive function will be recorded.


Condition Intervention Phase
Living Donors
Drug: Pregabalin
Drug: Sugar pill
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Perioperative Administration of Pregabalin in Laparoscopic Living Donor Nephrectomy (L-LDN) - an Adjuvance to Peroral Analgetic Treatment - a Randomized Controlled Study

Resource links provided by NLM:


Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Opioid consumption in milligrams Pain Score given as Numeric Rating Scale (NRS) [ Time Frame: Daily troughout the hospital stay, approx. 6 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Sedation and cognitive function [ Time Frame: Daily troughout the hospital stay, approx. 6 days ] [ Designated as safety issue: No ]

Enrollment: 80
Study Start Date: February 2010
Study Completion Date: December 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pregabalin Drug: Pregabalin
150 mg x 2 daily for 2 days
Other Name: Lyrica ATC-nr.: NO3A X 160
Placebo Comparator: Sugar pill Drug: Sugar pill
1 tablet x 2 daily, for 2 days

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • >18, < 75 years
  • healthy patients accepted for laparoscopic living donor nephrectomy

Exclusion Criteria:

  • not familiar to the Norwegian language (spoken and written)
  • allergic to one or more of the medication given in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01059331

Locations
Norway
Oslo Universitetssykehus, Rikshospitalet
Oslo, Norway, N-0027
Sponsors and Collaborators
Oslo University Hospital
Investigators
Principal Investigator: Audun Stubhaug, dr.med. Universitetet i Oslo, Rikshospitaelt, Anestesi- og intensivavdelingen
  More Information

Publications:
Responsible Party: Marianne Myhre, cand.med., Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01059331     History of Changes
Other Study ID Numbers: 2009/1286-1
Study First Received: January 28, 2010
Last Updated: March 20, 2014
Health Authority: Norway:National Committee for Medical and Health Research Ethics
Norway: Norwegian Medicines Agency
Norway: Data Protection Authority
Norway: Directorate of Health

Keywords provided by Oslo University Hospital:
Kidney

Additional relevant MeSH terms:
Pregabalin
Analgesics
Anticonvulsants
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014